Review Article J Integral Sci, 2026, 9[1], 12-15

Journal of Integral Sciences
[An International Open Access Journal]
Available at www.jisciences.com ISSN: 2581-5679

NEURALINK IN THE PHARMACEUTICAL FIELD: A COMPREHENSIVE REVIEW OF BRAIN–COMPUTER INTERFACE APPLICATIONS IN DRUG DEVELOPMENT AND NEUROLOGICAL THERAPY

K.KISHORE[1], M.UMAMAHESHWARI[1], P.DHANALAXMI, G.TEJASWI[1], V.SAILAJA[1], RAMAIAH MADDI[2]

Department of Pharmacy Practice, Maharajah's College of Pharmacy, Phool Baugh, Vizianagaram – 535002, A.P., India
Department of Pharmacognosy, Maharajah's College of Pharmacy, Phool Baugh, Vizianagaram – 535002, A.P., India

Received: 14-02-2026 Revised: 21-03-2026 Accepted: 09-04-2026

ABSTRACT

Recent developments in neurotechnology have created new possibilities for advancing biomedical and pharmaceutical research. One of the most promising innovations is the brain–computer interface (BCI), a technology that enables direct communication between the human brain and external computing systems. Neuralink, a neurotechnology company established by Elon Musk, is developing high-bandwidth implantable neural interfaces capable of both recording and stimulating brain activity. These devices use ultra-thin electrode threads implanted into the brain to capture neuronal signals and transmit them wirelessly to computers for analysis. Such technology has significant implications for pharmaceutical science, particularly in areas such as neurological drug discovery, personalized treatment strategies, and real-time therapeutic monitoring. By providing continuous observation of neural responses to medications, Neuralink may accelerate the development of new drugs, enhance clinical trial evaluation, and support precision medicine approaches for neurological conditions including Parkinson's disease, epilepsy, major depressive disorder, and Alzheimer's disease. This review paper analyzes the technological principles behind Neuralink systems and discusses their potential applications in pharmaceutical research. Additionally, it evaluates the benefits, challenges, ethical considerations, and future research directions associated with integrating brain–computer interface technology into pharmaceutical development.

Keywords: Neuralink, Brain-Computer Interface, Neurotechnology, Drug Development, Pharmaceutical Research, Personalized Medicine.

***Corresponding Author**
Dr. Ramaiah Maddi

DOI: https://doi.org/10.37022/jis.v9i1.132

Produced and Published by
South Asian Academic Publications

1. INTRODUCTION

The human brain is widely recognized as one of the most complex biological systems. It contains billions of neurons that communicate through electrical and chemical signaling processes. A deeper understanding of these neural interactions is essential for the development of effective therapies for neurological diseases. However, conventional pharmaceutical research often relies on indirect measurements of brain activity such as behavioral observation or imaging methods, which provide limited insight into neuronal dynamics. In recent years, advances in neuroengineering have introduced brain–computer interfaces (BCIs) as a promising solution for directly monitoring neural activity [1]. BCIs capture electrical signals from neurons, analyze them using computational algorithms, and convert them into commands that allow communication between the brain and external devices [2-6].

One of the most notable developments in this domain is Neuralink, which focuses on designing implantable neural interfaces capable of recording high- resolution brain signals. Neuralink devices employ thousands of microelectrodes embedded within the brain to detect neuronal activity and transmit the data wirelessly to external processing systems.

The pharmaceutical sector has shown growing interest in this technology because it provides a new method for understanding brain function and evaluating how drugs affect neural circuits. Traditional drug discovery processes are often time-consuming and expensive due to limited knowledge of neurological mechanisms. By offering real-time neural data, Neuralink technology may help researchers design more effective therapies and optimize pharmaceutical treatment strategies.

This article reviews the technological foundations of Neuralink systems and examines their potential role in pharmaceutical research, particularly in drug discovery, clinical trial monitoring, and personalized medicine.

2. OVERVIEW OF BRAIN–COMPUTER INTERFACES

Brain–computer interfaces are technological systems designed to establish a direct communication pathway between the brain and external electronic devices. Unlike traditional communication pathways that rely on muscular activity, BCIs translate neural signals directly into digital commands.

These systems operate by capturing neural signals, processing the data through computational algorithms, and generating outputs that control devices or stimulate neural tissue. BCI technologies are increasingly used in healthcare to assist patients with neurological impairments.

2.1 Components of BCI Systems

A standard BCI system typically includes several functional components:

Signal acquisition unit – collects neural signals using electrodes or sensors placed on or within the brain.[7]

Signal processing module – filters noise and processes neural data to identify meaningful patterns.

Feature extraction and classification algorithms – interpret neural signals and categorize them into specific commands [4].

Output interface – translates processed signals into actions such as device control or therapeutic stimulation.

BCI technologies can be classified into three categories based on electrode placement:

1. Invasive BCIs – electrodes implanted directly into brain tissue.
2. Semi-invasive BCIs – electrodes placed beneath the skull but outside the brain.
3. Non-invasive BCIs – electrodes positioned on the scalp. Among these, invasive BCIs provide the highest signal quality and resolution. Neuralink falls within this category because its electrodes interact directly with neuronal networks.

2.2 Medical Applications of BCIs

Brain–computer interface technology has been explored for numerous healthcare applications, including:

- Neuroprosthetic systems
- Rehabilitation therapies for stroke patients
- Communication tools for individuals with paralysis
- Monitoring and treatment of neurological disorders
- Cognitive assistance technologies
- Research suggests that BCIs could significantly improve the diagnosis and treatment of neurological conditions by enabling direct monitoring of neural activity and facilitating targeted therapeutic interventions

3. NEURALINK TECHNOLOGY

Neuralink represents one of the most advanced invasive BCI technologies currently under development. Its primary objective is to create a high-bandwidth neural communication platform that links the human brain with digital devices.

3.1 Structure of the Neuralink Device

The Neuralink implant consists of several integrated components designed to capture and process neural signals:

- A compact neural processing chip embedded within the skull Ultra-thin electrode threads that interface with neurons
- A robotic surgical system used for precise implantation Wireless communication hardware that transmits neural data
- These electrode threads detect electrical activity produced by neurons and send the recorded signals to external computers where they are analyzed using specialized software.

3.2 High-Bandwidth Neural Recording

Conventional neural implants typically record signals from a relatively small number of neurons. In contrast, Neuralink technology significantly increases the number of recording channels, allowing researchers to collect neural data from thousands of neurons simultaneously.

This capability enables scientists to study complex neural networks and examine how different regions of the brain interact during cognitive activities or pharmacological treatments.

3.3 Human Trials and Development

Neuralink has received regulatory approval to conduct clinical trials involving implantable brain devices designed to restore neurological function. Early experimental trials have demonstrated that individuals with implanted devices can control digital interfaces using neural signals alone [2].

These results highlight the potential of Neuralink technology to support future medical applications, including the treatment of neurological disorders and advanced neuroprosthetic systems [8].

4. APPLICATIONS OF NEURALINK IN THE PHARMACEUTICAL INDUSTRY

4.1 Drug Discovery and Development

Developing medications for neurological diseases presents significant challenges due to the complexity of brain circuitry. Neuralink technology could allow researchers to monitor neuronal responses to pharmaceutical compounds in real time.

This approach may help scientists:

Identify neural pathways influenced by specific drugs Evaluate therapeutic effectiveness more accurately reduce the duration of drug development cycles

Direct neural monitoring could provide valuable insights into the mechanisms through which medications affect the brain [17].

4.2 Clinical Trials and Drug Evaluation

Clinical trials are essential for assessing the safety and efficacy of pharmaceutical treatments. Traditionally, these trials rely heavily on behavioral observations and patient-reported outcomes. Neuralink technology could enhance clinical trials by enabling researchers to measure neural responses objectively. Continuous neural monitoring may also allow earlier detection of adverse drug effects [17].

4.3 Personalized Medicine

Another promising application of Neuralink technology is the advancement of personalized medicine.

Since patients often respond differently to medications, continuous neural monitoring could help physicians tailor treatments according to individual neural responses. This strategy may reduce side effects while improving therapeutic effectiveness [11].

Personalized treatment approaches may be particularly useful for disorders such as depression, epilepsy, Parkinson's disease, and Alzheimer's disease [8].

4.4 Neurological Disease Treatment

In addition to pharmaceutical research, Neuralink implants may function as therapeutic neuromodulation devices capable of stimulating targeted brain regions.

Examples include:

Reducing tremors in Parkinson's disease through electrical stimulation Detecting and controlling epileptic seizures

Modulating neural circuits associated with severe depression

Combining pharmaceutical therapy with neural stimulation could significantly improve treatment outcomes [10].

4.5 Neuropharmacology Research

Neuralink technology also has the potential to advance neuropharmacology research by providing direct access to neural circuitry.

Scientists may investigate:

Neurotransmitter interactions within neural networks Brain plasticity during pharmaceutical treatment Long-term neural adaptations to medications

These insights could support the development of more precise and effective neurological drugs.

5. Advantages of Neuralink in Pharmaceutical Research Real-Time Neural Monitoring

Continuous observation of brain activity allows researchers to detect immediate neural responses to pharmaceutical compounds [6].

Enhanced Drug Targeting

Detailed neural data can help identify specific brain regions associated with disease, enabling targeted therapy development [5].

Accelerated Drug Discovery

Real-time neural measurements may reduce the time required to identify effective drug candidates [18].

Improved Clinical Trial Outcomes

Accurate monitoring of drug responses could decrease the likelihood of late- stage clinical trial failures.

Integration with Artificial Intelligence

Combining Neuralink data with machine learning algorithms may enable predictive models for drug discovery and disease progression.

6. Challenges and Limitations Surgical Risks

Implanting electrodes into the brain requires complex neurosurgical procedures that carry risks such as infection or tissue damage [27].

Ethical Concerns

The ability to record and analyze neural signals raises ethical questions related to privacy, consent, and potential misuse of brain data.

Regulatory Barriers

Medical approval for implantable neurotechnology requires extensive clinical testing and regulatory oversight.

Data Security

Neural data are highly sensitive, and protecting this information from unauthorized access is essential [28].

7. FUTURE PERSPECTIVES

The future role of Neuralink in pharmaceutical science appears highly promising. Several emerging developments may accelerate its adoption.

Artificial Intelligence Integration

AI-based algorithms may analyze neural data to identify disease biomarkers and predict drug responses.

Closed-Loop Neurotherapeutic Systems

Future implants may automatically detect abnormal neural activity and deliver targeted treatment.

Digital Therapeutics

BCI systems could become integrated with digital health platforms that combine software, medical devices, and pharmaceutical interventions.

Large-Scale Clinical Research

Ongoing clinical trials will provide important insights into the long-term safety and effectiveness of Neuralink technology.

8. CONCLUSION

Neuralink represents a significant breakthrough in neurotechnology with important implications for pharmaceutical research and neurological healthcare. By enabling direct communication between the brain and digital systems, Neuralink technology provides unprecedented insight into neural activity and brain function. Although several challenges remain-including surgical risks, ethical considerations, and regulatory approval-the potential benefits of this technology are substantial. Continued research and collaboration among neuroscientists, engineers, and pharmaceutical researchers will be essential for unlocking the full potential of brain–computer interface technology.

Ultimately, the integration of neuroscience, artificial intelligence, and pharmaceutical science may usher in a new era of precision neurotherapeutics, where treatments are customized according to the unique neural profiles of individual patients.

9. FUNDING

Nil

10. INFORM CONSENTS AND ETHICAL DECLARATIONS

Not applicable

11. ACKNOWLEDGEMENT

Authors are thankful to the management of, Maharajah's College of Pharmacy.

12. AUTHOR CONTRIBUTION

All authors contributed equally.

9. REFERENCES

1. Musk E, et al. An integrated brain–machine interface platform with thousands of channels. *J Med Internet Res.* 2019.
2. Shih JJ, Krusienski DJ, Wolpaw JR. Brain–computer interfaces in medicine. *Mayo Clin Proc.* 2012.
3. Lavazza A. Neuralink's brain–computer interfaces: medical innovations and future prospects. *Front Hum Dyn.* 2025.
4. Deng Q, et al. Application and future directions of brain–computer interfaces. *Neurotechnol Rev.* 2025.
5. Parikh PM. Neuralink and brain–computer interface: exciting times ahead. *J Clin Med.* 2024.
6. Sah SK. Impact of brain–computer interfaces in healthcare. *J Biomed Pharm Sci.* 2024.
7. Boonstra JT. Ethical imperatives in the commercialization of brain–computer interfaces. *Neuroethics Rev.* 2025.
8. Huang J, et al. Bibliometric analysis of brain–computer interface applications. *J Multidiscip Healthc.* 2025.
9. Alkaff ZA, et al. Applications of brain–computer interface in healthcare. In: IntechOpen; 2024.
10. Neuralink. Brain–computer interface technology overview. Neuralink Official Website.
11. Wolpaw JR, Wolpaw EW. *Brain–computer interfaces: principles and practice.* Oxford: Oxford University Press; 2012.
12. Nicolelis MAL, Lebedev MA. Principles of neural ensemble physiology underlying the operation of brain–machine interfaces. *Nat Rev Neurosci.* 2017.
13. Jackson A, Zimmermann JB. Neural interfaces for the brain and spinal cord. *Cold Spring Harb Perspect Med.* 2012.
14. Lebedev MA, Nicolelis MAL. Brain–machine interfaces: past, present and future. *Trends Neurosci.* 2006.
15. Borton D, Yin M, Aceros J, Nurmikko A. An implantable wireless neural interface for recording cortical circuit dynamics. *Nat Commun.* 2013.
16. Steinmetz NA, et al. Neuropixels 2.0: a miniaturized high-density probe for stable, long-term brain recordings. *Science.* 2021.
17. Bouton CE, et al. Restoring cortical control of functional movement in a human with quadriplegia. *Nature.* 2016.
18. Fetz EE. Restoring motor function with bidirectional neural interfaces. *Prog Brain Res.* 2015.
19. Schwartz AB, Cui XT, Weber DJ, Moran DW. Brain-controlled interfaces: movement restoration with neural prosthetics. *Neuron.* 2006.
20. Donoghue JP. Connecting cortex to machines: recent advances in brain interfaces. *Nat Neurosci.* 2002.
21. Farina D, Aszmann O. Bionic limbs: clinical reality and academic promises. *Sci Transl Med.* 2014.
22. Chaudhary U, Birbaumer N, Ramos-Murguialday A. Brain–computer interfaces for communication and rehabilitation. *Nat Rev Neurol.* 2016.
23. Rao RPN. *Brain–computer interfacing: an introduction.* Cambridge: Cambridge University Press; 2013.
24. Velliste M, et al. Cortical control of a prosthetic arm for self-feeding. *Nature.* 2008.
25. Birbaumer N. Breaking the silence: brain–computer interfaces for communication and motor control. *Psychophysiology.* 2006.
26. Lebedev MA, Nicolelis MAL. Brain–machine interfaces: from basic science to neuroprostheses and neurorehabilitation. *Physiol Rev.* 2017.
27. Flesher SN, et al. Intracortical microstimulation of human somatosensory cortex. *Sci Transl Med.* 2016.
28. Collinger JL, et al. High-performance neuroprosthetic control by an individual with tetraplegia. *Lancet.* 2013.
29. Vansteensel MJ, et al. Fully implanted brain–computer interface in a locked-in patient. *N Engl J Med.* 2016.
30. Shenoy KV, Carmena JM. Combining decoder design and neural adaptation in brain–machine interfaces. *Neuron.* 2014.